Alternative splicing of the IgIII loop of fibroblast growth factor receptors (FGFRs) 1–3 produces b- and c-variants of the receptors with distinctly different biological impact based on their distinct ligand-binding spectrum. Tissue-specific expression of these splice variants regulates interactions in embryonic development, tissue maintenance and repair, and cancer. Alterations in FGFR2 splicing are involved in epithelial mesenchymal transition that produces invasive, metastatic features during tumor progression. Recent research has elucidated regulatory factors that determine the splice choice both on the level of exogenous signaling events and on the RNA-protein interaction level. Moreover, methodology has been developed that will enable the in depth analysis of splicing events during tumorigenesis and provide further insight on the role of FGFR 1–3 IIIb and IIIc in the pathophysiology of various malignancies. This paper aims to summarize expression patterns in various tumor types and outlines possibilities for further analysis and application. 1. Introduction Fibroblast growth factors (FGFs) are a large family of 23 ligands that serve crucial functions in embryonic development as well as in the adult organisms (for review see [1]). They mediate their signals via a small subfamily of 4 tyrosine kinase receptors (FGFR 1–4). This is a small number of receptors for a large group of ligands, but the system gains significant complexity from the formation of heterodimers as well as a high frequency of alternative splicing events [2, 3] that can be grouped in 3 categories. These categories are (1) the deletion of autoinhibitory domains close to the N- or the C-terminus of the proteins which produces more active and frequently oncogenic receptor variants [4, 5], (2) the IIIb and IIIc variants which are produced by alternative exon usage in the ligand-binding domain [2], and (3) soluble variants that come from exclusion of the exon that codes for the transmembrane region [6, 7]. All of these molecules display distinct biological activities. The IIIb and IIIc variations have been described for FGFRs 1–3 and probably have the strongest impact as they alter the ligand-binding portion of the affected FGFR [8]. This review will therefore focus on the IIIb/IIIc splice variants, their biological function, and the regulation of their formation especially in cancer. It will also describe novel methods for in vitro and in vivo monitoring. 2. Structure and Function of FGFRs 2.1. Expression and Splice Variants The FGFR-genes consist of up to 20 exons that together code
References
[1]
A. Beenken and M. Mohammadi, “The FGF family: biology, pathophysiology and therapy,” Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 235–253, 2009.
[2]
V. P. Eswarakumar, I. Lax, and J. Schlessinger, “Cellular signaling by fibroblast growth factor receptors,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 139–149, 2005.
[3]
D. Givol and A. Yayon, “Complexity of FGF receptors: genetic basis for structural diversity and functional specificity,” FASEB Journal, vol. 6, no. 15, pp. 3362–3369, 1992.
[4]
W. Jin, I. E. McCutcheon, G. N. Fuller, E. S. C. Huang, and G. J. Cote, “Fibroblast growth factor receptor-1 α-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors,” Cancer Research, vol. 60, no. 5, pp. 1221–1224, 2000.
[5]
A. B. Moffa, S. L. Tannheimer, and S. P. Ethier, “Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells,” Molecular Cancer Research, vol. 2, no. 11, pp. 643–652, 2004.
[6]
S. Ezzat, L. Zheng, S. Yu, and S. L. Asa, “A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 287, no. 1, pp. 60–65, 2001.
[7]
L. M. Sturla, A. E. Merrick, and S. A. Burchill, “FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells,” British Journal of Cancer, vol. 89, no. 7, pp. 1276–1284, 2003.
[8]
X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz, “Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family,” Journal of Biological Chemistry, vol. 281, no. 23, pp. 15694–15700, 2006.
[9]
N. Rebscher, C. Deichmann, S. Sudhop, J. H. Fritzenwanker, S. Green, and M. Hassel, “Conserved intron positions in FGFR genes reflect the modular structure of FGFR and reveal stepwise addition of domains to an already complex ancestral FGFR,” Development Genes and Evolution, vol. 219, no. 9-10, pp. 455–468, 2009.
[10]
Y. Zhang, M. C. Gorry, J. C. Post, and G. D. Ehrlich, “Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family,” Gene, vol. 230, no. 1, pp. 69–79, 1999.
[11]
W. Jin, E. S. C. Huang, W. Bi, and G. J. Cote, “Redundant intronic repressors function to inhibit fibroblast growth factor receptor-1 α-exon recognition in glioblastoma cells,” Journal of Biological Chemistry, vol. 274, no. 39, pp. 28035–28041, 1999.
[12]
P. Zhang, J. S. Greendorfer, J. Jiao, S. C. Kelpke, and J. A. Thompson, “Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES,” Archives of Biochemistry and Biophysics, vol. 450, no. 1, pp. 50–62, 2006.
[13]
S. Vainikka, J. Partanen, P. Bellosta et al., “Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction,” EMBO Journal, vol. 11, no. 12, pp. 4273–4280, 1992.
[14]
E. N. Meyers, M. Lewandoski, and G. R. Martin, “An Fgf8 mutant allelic series generated by Cre-and Flp-mediated recombination,” Nature Genetics, vol. 18, no. 2, pp. 136–141, 1998.
[15]
N. Turner and R. Grose, “Fibroblast growth factor signalling: from development to cancer,” Nature Reviews Cancer, vol. 10, no. 2, pp. 116–129, 2010.
[16]
J. Partanen, L. Schwartz, and J. Rossant, “Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos,” Genes and Development, vol. 12, no. 15, pp. 2332–2344, 1998.
[17]
L. de Moerlooze, B. Spencer-Dene, J. M. Revest, M. Hajihosseini, I. Rosewell, and C. Dickson, “An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis,” Development, vol. 127, no. 3, pp. 483–492, 2000.
[18]
V. P. Eswarakumar, E. Monsonego-Ornan, M. Pines, I. Antonopoulou, G. M. Morriss-Kay, and P. Lonai, “The IIIc alternative of Fgfr2 is a positive regulator of bone formation,” Development, vol. 129, no. 16, pp. 3783–3793, 2002.
[19]
J. S. Colvin, B. A. Bohne, G. W. Harding, D. G. McEwen, and D. M. Ornitz, “Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3,” Nature Genetics, vol. 12, no. 4, pp. 390–397, 1996.
[20]
M. Weinstein, X. Xu, K. Ohyama, and C. X. Deng, “FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung,” Development, vol. 125, no. 18, pp. 3615–3623, 1998.
[21]
C. Wuechner, A. C. S. Nordqvist, A. Winterpacht, B. Zabel, and M. Schalling, “Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse,” International Journal of Developmental Biology, vol. 40, no. 6, pp. 1185–1188, 1996.
[22]
P. Kettunen, I. Karavanova, and I. Thesleff, “Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9,” Developmental Genetics, vol. 22, no. 4, pp. 374–385, 1998.
[23]
D. P. C. Rice, R. Rice, and I. Thesleff, “Fgfr mRNA isoforms in craniofacial bone development,” Bone, vol. 33, no. 1, pp. 14–27, 2003.
[24]
A. Orr-Urtreger, M. T. Bedford, T. Burakova et al., “Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2),” Developmental Biology, vol. 158, no. 2, pp. 475–486, 1993.
[25]
P. Lonai, “Epithelial mesenchymal interactions, the ECM and limb development,” Journal of Anatomy, vol. 202, no. 1, pp. 43–50, 2003.
[26]
P. W. Finch and J. S. Rubin, “Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair,” Advances in Cancer Research, vol. 91, pp. 69–136, 2004.
[27]
J. M. Veltmaat, A. A. Mailleux, J. P. Thiery, and S. Bellusci, “Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation,” Differentiation, vol. 71, no. 1, pp. 1–17, 2003.
[28]
C. Tickle and A. Münsterberg, “Vertebrate limb development—the early stages in chick and mouse,” Current Opinion in Genetics and Development, vol. 11, no. 4, pp. 476–481, 2001.
[29]
S. Barrientos, O. Stojadinovic, M. S. Golinko, H. Brem, and M. Tomic-Canic, “Growth factors and cytokines in wound healing,” Wound Repair and Regeneration, vol. 16, no. 5, pp. 585–601, 2008.
[30]
S. Braun, U. Auf Dem Keller, H. Steiling, and S. Werner, “Fibroblast growth factors in epithelial repair and cytoprotection,” Philosophical Transactions of the Royal Society B, vol. 359, no. 1445, pp. 753–757, 2004.
[31]
R. Grose and S. Werner, “Wound-healing studies in transgenic and knockout mice,” Applied Biochemistry and Biotechnology, vol. 28, no. 2, pp. 147–166, 2004.
[32]
C. Heinzle, H. Sutterlüty, M. Grusch, B. Grasl-Kraupp, W. Berger, and B. Marian, “Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 15, no. 7, pp. 829–846, 2011.
[33]
E. Scotet and E. Houssaint, “The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific,” Biochimica et Biophysica Acta, vol. 1264, no. 2, pp. 238–242, 1995.
[34]
B. Murgue, S. Tsunekawa, I. Rosenberg, M. DeBeaumont, and D. K. Podolsky, “Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium,” Cancer Research, vol. 54, no. 19, pp. 5206–5211, 1994.
[35]
A. Vidrich, J. M. Buzan, C. Ilo, L. Bradley, K. Skaar, and S. M. Cohn, “Fibroblast Growth Factor Receptor-3 Is Expressed in Undifferentiated Intestinal Epithelial Cells during Murine Crypt Morphogenesis,” Developmental Dynamics, vol. 230, no. 1, pp. 114–123, 2004.
[36]
T. Shimokawa, Y. Furukawa, M. Sakai et al., “Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex,” Cancer Research, vol. 63, no. 19, pp. 6116–6120, 2003.
[37]
G. Sonvilla, S. Allerstorfer, S. St？ttner et al., “FGF18 in colorectal tumour cells: autocrine and paracrine effects,” Carcinogenesis, vol. 29, no. 1, pp. 15–24, 2008.
[38]
G. Sonvilla, S. Allerstorfer, C. Heinzle et al., “Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration,” British Journal of Cancer, vol. 102, no. 7, pp. 1145–1156, 2010.
[39]
A. Schulenburg, P. Cech, I. Herbacek et al., “CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msiI) and ephrin B2 receptor (EphB2),” Journal of Pathology, vol. 213, no. 2, pp. 152–160, 2007.
[40]
V. Knights and S. J. Cook, “De-regulated FGF receptors as therapeutic targets in cancer,” Pharmacology and Therapeutics, vol. 125, no. 1, pp. 105–117, 2010.
[41]
E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, “Roles of fibroblast growth factor receptors in carcinogenesis,” Molecular Cancer Research, vol. 8, no. 11, pp. 1439–1452, 2010.
[42]
Y. Katoh and M. Katoh, “FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review),” International Journal of Molecular Medicine, vol. 23, no. 3, pp. 307–311, 2009.
[43]
C. L. Chaffer, J. P. Brennan, J. L. Slavin, T. Blick, E. W. Thompson, and E. D. Williams, “Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2,” Cancer Research, vol. 66, no. 23, pp. 11271–11278, 2006.
[44]
A. Matsubara, M. Kan, S. Feng, and W. L. McKeehan, “Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2,” Cancer Research, vol. 58, no. 7, pp. 1509–1514, 1998.
[45]
D. Ricol, D. Cappellen, A. El Marjou et al., “Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer,” Oncogene, vol. 18, no. 51, pp. 7234–7243, 1999.
[46]
J. P. Thiery and J. P. Sleeman, “Complex networks orchestrate epithelial-mesenchymal transitions,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131–142, 2006.
[47]
H. Fischer, N. Taylor, S. Allerstorfer et al., “Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3408–3419, 2008.
[48]
M. Kornmann, T. Ishiwata, K. Matsuda et al., “IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells,” Gastroenterology, vol. 123, no. 1, pp. 301–313, 2002.
[49]
S. Allerstorfer, G. Sonvilla, H. Fischer et al., “FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities,” Oncogene, vol. 27, no. 30, pp. 4180–4190, 2008.
[50]
T. Shirakihara, K. Horiguchi, K. Miyazawa et al., “TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition,” EMBO Journal, vol. 30, no. 4, pp. 783–795, 2011.
[51]
X. Wu, M. Kan, F. Wang, C. Jin, C. Yu, and W. L. McKeehan, “A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1,” Cancer Research, vol. 61, no. 13, pp. 5295–5302, 2001.
[52]
J. H. Jang, “Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis,” Oncogene, vol. 24, no. 5, pp. 945–948, 2005.
[53]
N. Auersperg, “The origin of ovarian carcinomas: a unifying hypothesis,” International Journal of Gynecological Pathology, vol. 30, no. 1, pp. 12–21, 2011.
[54]
J. M. Dobson, S. Samuel, H. Milstein, K. Rogers, and J. L. N. Wood, “Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs,” Journal of Small Animal Practice, vol. 43, no. 6, pp. 240–246, 2002.
[55]
C. R. Dorn, D. O. Taylor, R. Schneider, H. H. Hibbard, and M. R. Klauber, “Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County,” Journal of the National Cancer Institute, vol. 40, no. 2, pp. 307–318, 1968.
[56]
J. M. Liptak and L. Forrest, “Soft tissue sarcomas,” in Withrow & MacEwens`s Small Animal Clinical Oncology, S. J. Withrow and D. M. Vail, Eds., pp. 425–454, Sauners Elsevier, St.Louis, Mo, USA, 2007.
[57]
M. L. Hauck, “Injection site sarcomas,” in Veterinary Clinics of North America—Update in Medical Oncology, B. E. Kitchell, Ed., pp. 553–571, WB Saunders, Philadelphia, Pa, USA, 2003.
[58]
H. A. Steinhoff, In vitro expression of fibroblast growth factor receptors in soft tissue sarcoma, Diploma thesis, Medical University Vienna, Vienna, Austria, 2009.
[59]
E. Gilbert, F. Del Gatto, P. Champion-Arnaud, M. C. Gesnel, and R. Breathnach, “Control of BEK and K-SAM splice sites in alternative splicing of the fibroblast growth factor receptor 2 pre-mRNA,” Molecular and Cellular Biology, vol. 13, no. 9, pp. 5461–5468, 1993.
[60]
A. Barrallo-Gimeno and M. A. Nieto, “The Snail genes as inducers of cell movement and survival: implications in development and cancer,” Development, vol. 132, no. 14, pp. 3151–3161, 2005.
[61]
P. Polakis, “Wnt signaling and cancer,” Genes and Development, vol. 14, no. 15, pp. 1837–1851, 2000.
[62]
P. Savagner, “Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition,” BioEssays, vol. 23, no. 10, pp. 912–923, 2001.
[63]
J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-Mesenchymal Transitions in Development and Disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
[64]
G. Yan, Y. Fukabori, G. McBride, S. Nikolaropolous, and W. L. McKeehan, “Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy,” Molecular and Cellular Biology, vol. 13, no. 8, pp. 4513–4522, 1993.
[65]
E. Scotet and E. Houssaint, “Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2,” Oncogene, vol. 17, no. 1, pp. 67–76, 1998.
[66]
J. H. Jang, K. H. Shin, Y. J. Park, R. J. Lee, W. L. McKeehan, and J. G. Park, “Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer,” Cancer Research, vol. 60, no. 15, pp. 4049–4052, 2000.
[67]
A. J. Matlin, F. Clark, and C. W. J. Smith, “Understanding alternative splicing: towards a cellular code,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 386–398, 2005.
[68]
L. A. Chasin, “Searching for splicing motifs,” Advances in Experimental Medicine and Biology, vol. 623, pp. 85–106, 2007.
[69]
E. Buratti and F. E. Baralle, “Influence of RNA secondary structure on the pre-mRNA splicing process,” Molecular and Cellular Biology, vol. 24, no. 24, pp. 10505–10514, 2004.
[70]
A. Hanamura, J. F. Cáceres, A. Mayeda, B. R. Franza, and A. R. Krainer, “Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors,” RNA, vol. 4, no. 4, pp. 430–444, 1998.
[71]
R. H. Hovhannisyan and R. P. Carstens, “Heterogeneous ribonucleoprotein M is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons,” Journal of Biological Chemistry, vol. 282, no. 50, pp. 36265–36274, 2007.
[72]
D. M. Mauger, C. Lin, and M. A. Garcia-Blanco, “hnRNP H and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc,” Molecular and Cellular Biology, vol. 28, no. 17, pp. 5403–5419, 2008.
[73]
C. C. Warzecha, T. K. Sato, B. Nabet, J. B. Hogenesch, and R. P. Carstens, “ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing,” Molecular Cell, vol. 33, no. 5, pp. 591–601, 2009.
[74]
C. C. Warzecha, P. Jiang, K. Amirikian et al., “An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition,” EMBO Journal, vol. 29, no. 19, pp. 3286–3300, 2010.
[75]
C. C. Warzecha, S. Shen, Y. Xing, and R. P. Carstens, “The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events,” RNA biology, vol. 6, no. 5, pp. 546–562, 2009.
[76]
A. Pandya-Jones and D. L. Black, “Co-transcriptional splicing of constitutive and alternative exons,” RNA, vol. 15, no. 10, pp. 1896–1908, 2009.
[77]
D. Auboeuf, E. Batsché, M. Dutertre, C. Muchardt, and B. W. O'Malley, “Coregulators: transducing signal from transcription to alternative splicing,” Trends in Endocrinology and Metabolism, vol. 18, no. 3, pp. 122–129, 2007.
[78]
R. F. Luco, M. Allo, I. E. Schor, A. R. Kornblihtt, and T. Misteli, “Epigenetics in alternative pre-mRNA splicing,” Cell, vol. 144, no. 1, pp. 16–26, 2011.
[79]
R. F. Luco and T. Misteli, “More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation,” Current Opinion in Genetics and Development, vol. 21, no. 4, pp. 366–372, 2011.
[80]
J. W. Shin, M. Min, F. Larrieu-Lahargue et al., “Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis,” Molecular Biology of the Cell, vol. 17, no. 2, pp. 576–584, 2006.
[81]
X. Zhu, K. Lee, S. L. Asa, and S. Ezzat, “Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells,” American Journal of Pathology, vol. 170, no. 5, pp. 1618–1628, 2007.
[82]
M. Chen and J. L. Manley, “Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches,” Nature Reviews Molecular Cell Biology, vol. 10, no. 11, pp. 741–754, 2009.
[83]
M. Hallegger, M. Llorian, and C. W. J. Smith, “Alternative splicing: global insights: minireview,” FEBS Journal, vol. 277, no. 4, pp. 856–866, 2010.
[84]
M. Dutertre, S. Vagner, and D. Auboeuf, “Alternative splicing and breast cancer,” RNA Biology, vol. 7, no. 4, pp. 403–411, 2010.
[85]
T. Metzner, A. Bedeir, G. Held et al., “Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition,” Journal of Investigative Dermatology, vol. 131, no. 10, pp. 2087–2095, 2011.
[86]
V. I. Bonano, S. Oltean, R. M. Brazas, and M. A. Garcia-Blanco, “Imaging the alternative silencing of FGFR2 exon IIIb in vivo,” RNA, vol. 12, no. 12, pp. 2073–2079, 2006.
[87]
E. A. Newman, S. J. Muh, R. H. Hovhannisyan et al., “Identification of RNA-binding proteins that regulate FGFR2 splicing through the use of sensitive and specific dual color fluorescence minigene assays,” RNA, vol. 12, no. 6, pp. 1129–1141, 2006.
[88]
S. Oltean, B. S. Sorg, T. Albrecht et al., “Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostrate tumors reveals unexpected epithelial mesenchymal plasticity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 38, pp. 14116–14121, 2006.
[89]
V. I. Bonano, S. Oltean, and M. A. Garcia-Blanco, “A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice,” Nature Protocols, vol. 2, no. 9, pp. 2166–2181, 2007.
[90]
S. Oltean, P. G. Febbo, and M. A. Garcia-Blanco, “Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo,” Clinical and Experimental Metastasis, vol. 25, no. 6, pp. 611–619, 2008.
[91]
J. P. Orengo, D. Bundman, and T. A. Cooper, “A bichromatic fluorescent reporter for cell-based screens of alternative splicing,” Nucleic Acids Research, vol. 34, no. 22, article E148, 2006.
[92]
A. Takeuchi, M. Hosokawa, T. Nojima, and M. Hagiwara, “Splicing reporter mice revealed the evolutionally conserved switching mechanism of tissue-specific alternative exon selection,” PloS One, vol. 5, no. 6, p. e10946, 2010.
[93]
N. C. Shaner, P. A. Steinbach, and R. Y. Tsien, “A guide to choosing fluorescent proteins,” Nature Methods, vol. 2, no. 12, pp. 905–909, 2005.
[94]
C. J. Powers, S. W. McLeskey, and A. Wellstein, “Fibroblast growth factors, their receptors and signaling,” Endocrine-Related Cancer, vol. 7, no. 3, pp. 165–197, 2000.
[95]
K. Motomura, A. Hagiwara, A. Komi-Kuramochi et al., “An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection,” Biochimica et Biophysica Acta—General Subjects, vol. 1780, no. 12, pp. 1432–1440, 2008.
[96]
O. E. Pardo, A. Arcaro, G. Salerno, S. Raguz, J. Downward, and M. J. Seckl, “Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis,” Journal of Biological Chemistry, vol. 277, no. 14, pp. 12040–12046, 2002.
[97]
O. E. Pardo, A. Lesay, A. Arcaro et al., “Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells,” Molecular and Cellular Biology, vol. 23, no. 21, pp. 7600–7610, 2003.
[98]
O. E. Pardo, C. Wellbrock, U. K. Khanzada et al., “FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B-Raf and S6K2,” EMBO Journal, vol. 25, no. 13, pp. 3078–3088, 2006.
[99]
J. Qing, X. Du, Y. Chen et al., “Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice,” Journal of Clinical Investigation, vol. 119, no. 5, pp. 1216–1229, 2009.
[100]
Z. Zhang, A. L. Stiegler, T. J. Boggon, S. Kobayashi, and B. Halmos, “EGFR-mutated lung cancer: a paradigm of molecular oncology,” Oncotarget, vol. 1, no. 7, pp. 497–514, 2010.
[101]
J. Gotzmann, A. N. M. Fischer, M. Zojer et al., “A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes,” Oncogene, vol. 25, no. 22, pp. 3170–3185, 2006.
[102]
M. Blaustein, F. Pelisch, and A. Srebrow, “Signals, pathways and splicing regulation,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 11, pp. 2031–2048, 2007.
[103]
S. Stamm, “Regulation of alternative splicing by reversible protein phosphorylation,” Journal of Biological Chemistry, vol. 283, no. 3, pp. 1223–1227, 2008.
[104]
C. F. Bourgeois, F. Lejeune, and J. Stevenin, “Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA,” Progress in Nucleic Acid Research and Molecular Biology, vol. 78, pp. 37–88, 2004.
[105]
S. H. Xiao and J. L. Manley, “Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2,” EMBO Journal, vol. 17, no. 21, pp. 6359–6367, 1998.
[106]
K. W. Lynch and A. Weiss, “A CD45 Polymorphism Associated with Multiple Sclerosis Disrupts an Exonic Splicing Silencer,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 24341–24347, 2001.
[107]
J. Xie and D. L. Black, “A CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels,” Nature, vol. 410, no. 6831, pp. 936–939, 2001.
[108]
S. J. Baker and E. P. Reddy, “Targeted inhibition of kinases in cancer therapy,” Mount Sinai Journal of Medicine, vol. 77, no. 6, pp. 573–586, 2010.
[109]
R. J. Van Alphen, E. A. C. Wiemer, H. Burger, and F. A. L. M. Eskens, “The spliceosome as target for anticancer treatment,” British Journal of Cancer, vol. 100, no. 2, pp. 228–232, 2009.
[110]
R. N. Singh, “Evolving concepts on human SMN pre-mRNA splicing,” RNA Biology, vol. 4, no. 1, pp. 7–10, 2007.
[111]
P. J. Shepard and K. J. Hertel, “The SR protein family,” Genome biology, vol. 10, no. 10, p. 242, 2009.
[112]
O. Fedorov, K. Huber, A. Eisenreich et al., “Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing,” Chemistry and Biology, vol. 18, no. 1, pp. 67–76, 2011.
[113]
M. Muraki, B. Ohkawara, T. Hosoya et al., “Manipulation of alternative splicing by a newly developed inhibitor of Clks,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 24246–24254, 2004.
[114]
D. G. Nowak, E. M. Amin, E. S. Rennel et al., “Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis,” Journal of Biological Chemistry, vol. 285, no. 8, pp. 5532–5540, 2010.
[115]
K. Thorsen, F. Mansilla, T. Schepeler et al., “Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway,” Molecular and Cellular Proteomics, vol. 10, no. 1, 2011.
[116]
B. Pilch, E. Allemand, M. Facompré et al., “Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506,” Cancer Research, vol. 61, no. 18, pp. 6876–6884, 2001.
[117]
J. Soret, N. Bakkour, S. Maire et al., “Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8764–8769, 2005.
[118]
J. Tazi, N. Bakkour, J. Soret et al., “Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives,” Molecular Pharmacology, vol. 67, no. 4, pp. 1186–1194, 2005.
[119]
Y. Mizui, T. Sakai, M. Iwata et al., “Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities,” Journal of Antibiotics, vol. 57, no. 3, pp. 188–196, 2004.
[120]
E. G. Folco, K. E. Coil, and R. Reed, “The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region,” Genes and Development, vol. 25, no. 5, pp. 440–444, 2011.
[121]
Y. Kotake, K. Sagane, T. Owa et al., “Splicing factor SF3b as a target of the antitumor natural product pladienolide,” Nature Chemical Biology, vol. 3, no. 9, pp. 570–575, 2007.
[122]
L. Fan, C. Lagisetti, C. C. Edwards, T. R. Webb, and P. M. Potter, “Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing,” ACS Chemical Biology, vol. 6, no. 6, pp. 582–589, 2011.
